OncoMatch/Clinical Trials/NCT04803318

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Is NCT04803318 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Combination of three inhibitors Trametinib, Everolimus and Lenvatinib for solid tumor, adult.

Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT04803318Data as of May 2026

Treatment: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib — To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Hepatocellular Carcinoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify